Photo via Pexels
CRISPR-Cas for epigenetic editing employs a deactivated Cas9 (dCas9) enzyme, fused with epigenetic modifying proteins, to precisely alter gene expression without making permanent changes to the underlying DNA sequence. This system can add or remove chemical marks (like methylation or acetylation) on DNA or histones, thereby "turning genes on or off" or modulating their activity. Leading research is conducted at the Broad Institute of MIT and Harvard, Gladstone Institutes, and companies like Epigenome, Inc. The technology is primarily in advanced research and preclinical development, showing promise in various disease models. In a notable achievement, researchers at the Salk Institute published in Cell in 2022, demonstrating the use of dCas9 to reverse age-related epigenetic changes and restore youthful gene expression patterns in mice, improving tissue regeneration. This offers a reversible and potentially safer alternative to traditional gene editing, which permanently alters the genome.
Editorial check
How this page is checked
Source trail
chromamedicine.com
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It Matters
Epigenetic dysregulation contributes to numerous complex diseases, including neurodegenerative disorders, metabolic syndromes, and many cancers, affecting billions worldwide. Mainstream epigenetic editing could offer novel therapies for conditions currently untreatable or poorly managed, by precisely correcting disease-causing gene expression patterns. Patients with genetic predispositions or age-related diseases stand to gain immensely; pharmaceutical companies with extensive epigenetic drug pipelines would be well-positioned, while those focused solely on DNA-level gene editing might face new competition. Challenges include precise delivery to target cells, ensuring the stability and specificity of epigenetic changes, and avoiding off-target effects across the epigenome. First-in-human trials could begin in 5-8 years, with broader therapeutic applications in 15-20 years. The US, with its strong biotech funding, is a key player, alongside European academic centers. A less obvious consequence is the potential for "epigenetic designer babies" or even reversing aging, raising profound ethical and societal questions about human enhancement and longevity.
Development Stage
Related
Scrintal
Scrintal is a visual knowledge canvas and note-taking tool developed by a startup, designed to help users think spatially and connect ideas on an infinite…
Have I Been Pwned (HIBP)
Have I Been Pwned (HIBP) is a free online service created by security expert Troy Hunt, designed to help people check if their email addresses or phone numbers…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.